The new criteria for classification of rheumatoid arthritis: what we need to know for clinical practice by Corrao, S. et al.
European Journal of Internal Medicine 22 (2011) 217–219
Contents lists available at ScienceDirect
European Journal of Internal Medicine
j ourna l homepage: www.e lsev ie r.com/ locate /e j imReview article
The new criteria for classiﬁcation of rheumatoid arthritis: what we need to know for
clinical practice☆
Salvatore Corrao ⁎, Luigi Calvo, Giuseppe Licata
Dipartimento Biomedico di Medicina Interna e Specialistica, University of Palermo, Italy☆ This manuscript had no ﬁnancial support or oth
sources. Moreover, all the authors have not any ﬁnanci
potential conﬂict of interest or the appearance of a con
this work.
⁎ Corresponding author. Laboratory of Clinical Ep
Knowledge Management, Dipartimento Biomedico di M
University of Palermo [Biomedical Department of Interna
Piazza delle Cliniche 2, 90147 Palermo, Italy. Tel.: +30
6552165.
E-mail address: s.corrao@tiscali.it (S. Corrao).
0953-6205/$ – see front matter © 2011 European Fede
doi:10.1016/j.ejim.2010.12.018a b s t r a c ta r t i c l e i n f oArticle history:
Received 4 December 2010
Received in revised form 19 December 2010
Accepted 22 December 2010
Available online 26 January 2011
Keywords:
Rheumatoid arthritis
Classiﬁcation criteria
Anti-citrullinated peptide autoantibodies
Bayesian reasoning
Likelihood ratio
Sensitivity and speciﬁcityThe new criteria for classiﬁcation of Rheumatoid Arthritis have been recently released. They incorporate the
anti-Citrullinated Protein antibody testing and the other classic criteria in a score system (the diagnosis of
deﬁnite rheumatoid arthritis is made by a total score≥6). These criteria try to meet the pressing needs to gain
sensitivity in early disease. Symptoms, elevated acute-phase response, serologic abnormality, joint
involvement were all considered for scoring after conﬁrming the presence of synovitis in at least 1 joint in
the absence of an alternative diagnosis that better explains the synovitis. However, no sensitivity and
speciﬁcity has been showed. Moreover, Area Under Curve of the Receiver Operating Characteristic curves (a
measure of performance of the test) was not optimal in almost two of the three studied cohorts. On the
contrary, the old criteria of the American College of Rheumatology had been tested to calculate sensitivity and
speciﬁcity. Moreover, sensitivity and speciﬁcity of anti-citrullinated peptide auto-antibodies are available for
clinical reasoning based on pre-test and post-test probabilities of the disease. The use of likelihood ratios
applied to both the old criteria and anti-citrullinated autoantibodies could help clinicians to effectively
manage early arthritis patients implementing Bayesian reasoning. Here, we tried to explain the methodology
applied to the body of knowledge currently available about rheumatoid arthritis for diagnostic decision-
making based on the Bayesian approach.© 2011 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.The 2010 Rheumatoid Arthritis classiﬁcation criteria were recently
published [1]. They try tomeet the pressing needs to gain sensitivity in
early disease. Symptoms, elevated acute-phase response, serologic
abnormality, joint involvement were all considered for scoring after
conﬁrming the presence of synovitis in at least 1 joint in the absence of
an alternative diagnosis that better explains the synovitis (Table 1).
Anti-Citrullinated Protein antibody testing was incorporated for the
ﬁrst time into the new diagnostic criteria. However, various issues
should be addressed. First of all, the paper does not report any
sensitivity and speciﬁcity of the new criteria whereas the old criteria
had reported these values. The whole formulation process was based
on a form of structured consent by expert opinion. On the contrary,
since three large cohorts were available, a statistically driven process
could be used toweight each criterion by likelihood ratios. Positive and
negative likelihood ratios (and their 95% Conﬁdence Intervals) coulder beneﬁts from commercial
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ration of Internal Medicine. Publishbe computed for groups with similar criteria. Thus, the property of
combining independent likelihood ratios could have been used for
implementation in clinical practice. Unfortunately, for these reasons,
the opportunity to put into practice an intriguing evidence based
approach has been missed out. Last but not least, the great effort that
wasmade seems to have brought forth amouse. If, on one hand, either
sensitivity and speciﬁcity or likelihood ratioswere not reported, on the
other hand, the overall accuracy seems poor. In particular, the Area
Under Curve for Receiver Operating Characteristic curves (which plot
sensitivity, or true positive rate, against 1-speciﬁcity, or false positive
rate, to individuate the best discriminating cut-off value of a
quantitative variable, as a score is) resulted good in the Norwegian
cohort (0.88) but insufﬁcient in both the French and Rotterdam ones
(b0.70). Even though they were always statistically signiﬁcant,
notable variability among the Receiver Operating Characteristic curves
of the three different cohorts raises many doubts about clinical
signiﬁcance. However, clinicians need clinically signiﬁcant tools for
clinical practice where statistical signiﬁcance is only a necessary but
not a sufﬁcient criterion. On the other hand, the old criteria were
developed in the 1987 revision using themethodof classiﬁcation trees.
This analysis pointed out a speciﬁcity of 89% and a sensitivity of about
84% for the rule requiring 4 out of 7 American College of Rheumatology
criteria. Moreover, in recent years, the anti-Citrullinated Peptide
autoantibodies have emerged as valuable serologic marker of
Rheumatoid Arthritis while Rheumatoid Factor is the only biomarkered by Elsevier B.V. All rights reserved.
Table 1
The 2010 Classiﬁcation Criteria for Rheuamtoid Arthritis (score is intended to be
computed on patients who have at least 1 joint with deﬁnite clinical synovitis (joint
swelling) without any other disease explanation).
Score
A. Joint involvement
a. large joint. 0
b. 2–10 large joints 1
c. 1–3 small joints (with or without involvement of large joints) 2
d. 4–10 small joints (with or without involvement of large joints) 3
e. ≥10 joints (at least 1 small joint) 5
B. Serology (at least 1 test result is needed for classiﬁcation)
a. Negative RF and negative ACPA 0
b. Low-positive RF or low-positive ACPA 2
c. High-positive RF or high-positive ACPA 3
C. Acute-phase reactants (at least 1 test result is needed for classiﬁcation)
a. Normal CRP and normal ESR 0
b. Abnormal CRP or abnormal ESR 1
D. Duration of symptoms
a. b6 weeks 0
b. ≥6 weeks 1
“Large joints” refers to shoulders, elbows, hips, knees, and ankles.
“Small joints” refers to the metacarpophalangeal joints, proximal interphalangeal
joints, second through ﬁfth metatarsophalangeal joints, thumb interphalangeal joints, and
wrists.
For more details, please refer to the main publication (1).
The diagnosis of deﬁnite rheumatoid arthritis is made by a total score ≥6.
RF: Rheumatoid Factor; ACPA: Anti-Citrullinated Peptide Autoantibodies; CRP:C
Reactive Protein; ESR: Erythrocyte Sedimentation Rate.
218 S. Corrao et al. / European Journal of Internal Medicine 22 (2011) 217–219considered by the above-mentioned old American College of Rheu-
matology criteria. The importance of anti-Citrullinated Peptide
autoantibodies consists in the best speciﬁcity in comparison with
Rheumatoid Factor in patients affected by early Rheumatoid Arthritis
[2,3]. Recently, a systematic review has been published on accuracy of
anti-Citrullinated Peptide autoantibodies for diagnosing early RA [4].
This analysis of 151 studies showed that sensitivity and speciﬁcity
were 57% (95%Conﬁdence Intervals, 51% to 63%) and96% (93% to 97%),
respectively (analysis refers only to 15 relevant cohort studies). Thus,
sensitivity and speciﬁcity of the old American College Rheumatoid
criteria are available to us as much the same data for anti-Citrullinated
Peptide antibodies. How can this information be utilized for clinical
practice? Sensitivity and speciﬁcity are stable characteristic of a test.
The Bayes' theorem demonstrates that the Likelihood Ratio of both a
positive and negative test allows to compute posterior probability
using different “a priori” probabilities [5]. In a few words Likelihood
Ratios are sufﬁciently stable characteristic of a test with more
informative power than sensitivity and speciﬁcity (usually cryptic
information for the clinician). Indeed, sensitivity and speciﬁcity are
useful parameterswhen they reach values near 100% (a negative result
of a test with sensitivity of 100% permits to exclude a disease while a
test with speciﬁcity of 100% is highly indicative of disease when it
results positive). On the contrary, Likelihood Ratio of a positive test
and of a negative one are always informative and easily usable.
Generally, a positive Likelihood Ratio N15 suggests a good probability
to diagnose a disease while a negative Likelihood Ratio b0.15 suggests
a good probability to exclude a disease [6]. However, Likelihood Ratios
have another very interesting characteristic: their values can be
multiplied between or among Likelihood Ratios for different tests. For
example, if we have two independent tests for a disease (anti-
Citrullinated Peptide antibodies and the old American College of
Rheumatology criteria are the case) we can multiply the positive
Likelihood Ratios by themselves. The old American College of
Rheumatology criteria have a positive Likelihood Ratio of 8.54 and a
negative Likelihood Ratio of 0.07 (computed from the original
sensitivity and speciﬁcity values of the American College of Rheuma-
tology criteria). Anti-Citrullinated Peptide antibodies have a positive
Likelihood Ratio of 14 and a negative Likelihood Ratio of 0.45 (data
computed from the above-mentioned systematic review). It is obviousthat none of the two diagnostic tests is easily usable in clinical practice
for diagnosing or excluding Rheumatoid arthritis. However if we
combine their values (positive Likelihood Ratios =8.54×14=120;
negative Likelihood Ratios=0.07×0.45=0.031) Likelihood Ratios
(positive and negative) became highly informative for an unexper-
ienced physician as well. Even if we consider their 95% Conﬁdence
Intervals remain highly informative and usable in different clinical
practice settings (e.g. general practitioner setting or a rheumatologic
outpatient clinic). Moreover, the use of combined information
simpliﬁes diagnostic utilization of anti-Citrullinated Peptide autoan-
tibody cut-off values. Indeed, Pietrapertosa et al [7], in another recent
paper, have correctly pointed out the importance of different cut-off
values to modify Likelihood Ratios according to Sackett lessons [6].
Indeed, different cut-off values can generate the so-called SPin
(Speciﬁcity In: high values for the highest speciﬁcity, consequently
to diagnose disease) and SNout (Sensitivity Out: low values for the
highest sensitivity, consequently to exclude disease). Indeed, high
anti-Citrullinated Peptide autoantibody cut-off value (N15.0 or
N30.0 U/mL, that correspond to positive Likelihood Ratios of 42 and
inﬁnity, respectively) could became very useful to diagnose early RA
much precociously, that is, when both American College of Rheuma-
tology criteria cannot be applicable (onset of symptoms b6 week) or
only one criterion is lacking to get a positive result.
However, as shown above, we can simply use two diagnostic test
(anti-Citrullinated Peptide autoantibodies and the old American
College of Rheumatology criteria) to easily reach diagnostic values
of positive or negative Likelihood Ratios.
Archibald Cochrane claimed needs for synthesis caused by
information overload [8]. The Cochrane network systematic reviews
have become the standard to summarize information toward
knowledge growth [9]. Now, we also need to organize information
to generate usable knowledge using both the available methodology
from clinical epidemiology and clinical research data [10]. We believe
that what we have explained in this manuscript goes toward this
direction. Scientiﬁc community and prominent journals oriented to
readership of clinical practitioners must continue to provide knowl-
edge support for ease clinical practice implementation. We strongly
claim that scientiﬁc knowledge had to be based on facts and not on
faith.
Learning points
• The new criteria for classiﬁcation of Rheumatoid Arthritis incorpo-
rate the anti-Citrullinated Protein antibody testing and the other
classic criteria in a score system. The diagnosis of deﬁnite
rheumatoid arthritis is made by a total score ≥6. These criteria
might be more useful for classiﬁcation of patients with early
arthritis disease. However, no sensitivity and speciﬁcity has been
showed. Moreover, Area Under Curve of the Receiver Operating
Characteristic curves (ameasure of performance of the test) was not
optimal in almost two of the three studied cohorts.
• On the contrary, the old criteria of the American College of
Rheumatology had been tested to calculate sensitivity and speciﬁc-
ity. Moreover, sensitivity and speciﬁcity of anti-citrullinated peptide
auto-antibodies are available for clinical reasoning based on pre-test
and post-test probabilities of the disease. The use of likelihood ratios
(see the text) applied to both the old criteria and anti-citrullinated
autoantibodies could help clinicians to effectively manage early
arthritis patients implementing Bayesian reasoning.
• Less than four of the old classiﬁcation criteria and negative anti-
citrullinated peptide autoantibodies allow to exclude rheumatoid
arthritis.
• Even If a patient had not sufﬁcient probability of disease (below four
of the old criteria) but the anti-citrullinated peptide autoantibodies
N15 U/mL, the diagnosis of rheumatoid arthritis could be set.
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